Replies to post #248 on Tianrong Internet Products and Services Inc (TIPS)

[Walker]

Wow. Great find. I thought that might be the company that acquired the shares but you just proved it. That is huge!!!

Lots of great info on their website. This could be one for the record books!!!

[Ownwallstreet]

Wow no kidding! Thank you for sharing!

[Walker]

To Summarize -

TIPS - This is huge - just filed their Q - https://www.otcmarkets.com/otcapi/company/financial-report/312466/content

From the filing:
MATERIAL SUBSEQUENT EVENT
Following the end of the quarter to 30 September 2021, the Company was notified that on 27 October 2021,
Wilton Management Limited (“the Acquirer”), a Company registered in United Arab Emirates, acquired
50,000,000 Restricted Ordinary Shares of $0.01 cents each in the share capital of the Company from Tianrong
Building Material Holdings Limited (“the Vendor”). Upon the transfer, the Acquirer became the majority
shareholder of the Company.

Phone # in the quarterly is for
[phone]
https://www.wiltongroup.com/

They are working on this in the medtech field. Medtech was also mentioned in the quarterly.

https://www.wiltongroup.com/wp-content/uploads/2021/02/Cambridge-Orthopaedic-Labs-Teaser-2021.pdf

Could be pretty big. FDA approval soon, disrupting the current fracture market.

A. Summarize the issuer’s business operations (If the issuer does not have current operations, state “no operations”)
Tianrong Internet Products and Services, Inc. is a development stage company that was formed to invest in early
stage medical companies.
The Company is presently in early stage discussions regarding several potential investment opportunities in the
medical space.
On September 10, 2021, the Company retained Wilton Corporate Finance as its adviser and investment manager, as
part of our revised business plan to invest in early stage MedTech and medical device companies.

Wilton Group - https://www.zoominfo.com/c/wilton-group-limited/128893065

Description
Wilton provides a personal and fully integrated range of advisory services to corporates, entrepreneurs, high net worth individuals and their families. Drawing ... Read More

Headquarters
Headquarters:

26 Grosvenor St, London, Greater London, W1K 4QW, United Kingdom
Phone
Phone:

[phone]
Website
Website:

www.wiltongroup.com

Employees:

120

Revenue:

$22 Million

[Walker]

Check this out -

https://www.wiltongroup.com/investors-support-could-revolutionise-fracture-treatment/


Investors Support Could Revolutionise Fracture Treatment
Funding for the development and launch of an innovative new medical device which could revolutionise the treatment of broken bones is being driven by Wilton Corporate Finance Limited.
Funding for the development and launch of an innovative new medical device which could revolutionise the treatment of broken bones is being driven by Wilton Corporate Finance Limited.

Wilton is managing the opportunity to invest into Cambridge Orthopaedic Labs (COL) as part of a £3.5m Enterprise Investment Scheme (“EIS”) eligible fundraising round, for a 38.7% stake in the business.

COL has developed a non-invasive external fixator (“PolyArmour”) of great potential to improve patient experience and outcomes as well as being cost effective and affordable for healthcare providers when compared to traditional, invasive procedures.

Led by an experienced, orthopaedic specialist management team, COL has published clinical trial results which support PolyArmour’s efficacy, while management estimates PolyArmour will be able to treat around two thirds of the estimated 18 million fractures which occur globally each year.

Senior figures at Wilton are backing the COL team. James Robson, Head of Financial Services at Wilton, explained: ‘During our discussions with the team at Cambridge Orthopaedic Labs, we were impressed with the world class combination of medical and commercial orthopaedic specialists and it quickly became clear to us that this was an initiative worthy of investment.’

Wilton Head of Corporate Finance, Paul Osbourn added that ‘while there is risk in any early stage investment, we believe that in PolyArmour, COL has developed a product that has already demonstrated that it can improve patient outcomes and do so via a treatment that patients and healthcare providers will both in general prefer. This is why we believe COL has a real chance of making an impact on a multi billion dollar annual global fracture treatment market.’

Wilton Managing Partner Tony Flanagan concluded that ‘people will always break bones and trauma patient treatments cannot be deferred. By reducing the need for invasive surgical treatments, PolyArmour can also help alleviate hospital capacity constraints. At Wilton we are happy to help innovative firms by offering them strategic and operational support. We believe investors will consider an attractive opportunity to finance at an early stage a business with tremendous potential and to help bring a valuable new product to market.’

To find out more, or to invest, access the virtual data room, which includes the investment teaser, IM and subscription agreement, or email [e-mail].

[ANTI-BAGHOLDER]

TIPS
Company is presently in early stage discussions regarding several potential investment opportunities in the medical space.
On September 10, 2021, the Company retained Wilton Corporate Finance as its adviser and investment manager, as part of our revised business plan to invest in early stage MedTech and medical device companies.

https://www.otcmarkets.com/otcapi/company/financial-report/312467/content